Johnson & Johnson closed $25.19 below its 52-week high ($168.85), which the company reached on September 4th.
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...
Valued at a market cap of $348.2 billion, Johnson & Johnson (JNJ) researches, develops, manufactures, and sells various ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback